Hematologic Malignancies

Indiana University

Questions discussed in this category

What is your approach to pRBC transfusion support for myeloma-related anemia?

How much weight do you give to a hgb/hct threshold versus symptoms?

In what clinical scenarios do you utilize venetoclax-based therapy in relapsed/refractory multiple myeloma?

Venetoclax has demonstrated efficacy in patients harboring t(11;14) mutations but is not FDA approved for MM. Can you expand on what situations you ma...

3 Answers available

Which patients with smoldering myeloma do you treat?

2 Answers available

Papers discussed in this category

JAMA, 2016-11-15

Clinical Practice Guidelines From the AABB: Red Blood Cell Transfusion Thresholds and Storage.

N Engl J Med,

A multicenter, randomized, controlled clinical trial of transfusion requirements in critical care. Transfusion Requirements in Critical Care Investigators, Canadian Critical Care Trials Group.

J Clin Oncol, 2019 Apr 10

Management of Cancer-Associated Anemia With Erythropoiesis-Stimulating Agents: ASCO/ASH Clinical Practice Guideline Update.

J Clin Oncol, 2020 Feb 21

Liberal Versus Restrictive Red Blood Cell Transfusion Thresholds in Hematopoietic Cell Transplantation: A Randomized, Open Label, Phase III, Noninferiority Trial.

Blood cancer journal, 2018-06-12

Risk stratification of smoldering multiple myeloma incorporating revised IMWG diagnostic criteria.

J. Clin. Oncol., 2019 Oct 25

Randomized Trial of Lenalidomide Versus Observation in Smoldering Multiple Myeloma.

JAMA Oncol,

Carfilzomib, Lenalidomide, and Dexamethasone Followed by Lenalidomide Maintenance for Prevention of Symptomatic Multiple Myeloma in Patients With High-risk Smoldering Myeloma: A Phase 2 Nonrandomized Controlled Trial.

Lancet Oncol, 2020 Oct 29

Venetoclax or placebo in combination with bortezomib and dexamethasone in patients with relapsed or refractory multiple myeloma (BELLINI): a randomised, double-blind, multicentre, phase 3 trial.

J Clin Oncol, 2021 Aug 13

Phase I Study of Venetoclax Plus Daratumumab and Dexamethasone, With or Without Bortezomib, in Patients With Relapsed or Refractory Multiple Myeloma With and Without t(11;14).

Blood Adv, 2021 Sep 01

Phase 2 study of venetoclax plus carfilzomib and dexamethasone in patients with relapsed/refractory multiple myeloma.

Hematologic Malignancies

Indiana University

Questions discussed in this category

Papers discussed in this category

Related Topics in Hematologic Malignancies